For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 243,226 | 186,331 | 235,992 | 227,442.75* |
| General and administrative expenses | 276,610 | 210,311 | 287,922 | 527,816.25* |
| Total operating expenses | 519,836 | 396,642 | 523,914 | 755,259* |
| Interest income | - | 9,206 | 448 | 6,228.75* |
| Gain on disposal of subsidiaries | - | 7,346,684 | - | - |
| Interest (expense) income | -112 | - | - | - |
| Other expense, net | - | - | - | 65,712* |
| Other income (expense), net | 31,006 | 42,930 | 136,565 | - |
| Total other income (expense), net | 30,894 | 7,398,820 | 137,013 | -59,483.25* |
| Income (loss) before tax expense | -488,942 | 7,002,178 | -386,901 | -814,742.25 |
| Loss from discontinued operation (net of tax) | - | -144,257 | - | - |
| Net income (loss) for the period | -488,942 | 6,857,921 | -386,901 | -814,742.25* |
| Foreign currency translation gain, net of taxes | - | - | -86,539 | 54,586.5* |
| Foreign currency translation (loss) gain, net of taxes | -30,963 | -380,403 | - | - |
| Total comprehensive income (loss) | -519,905 | 6,477,518 | -473,440 | -760,155.75 |
| Basic EPS | -0.38 | 0.31 | -0.02 | -0.037 |
| Diluted EPS | -0.38 | 0.31 | -0.02 | -0.037 |
| Basic Average Shares | 1,284,923 | 21,640,000 | 21,640,000 | 20,525,699 |
| Diluted Average Shares | 1,284,923 | 21,640,000 | 21,640,000 | 20,525,699 |
Advanced Biomed Inc. (ADVB)
Advanced Biomed Inc. (ADVB)